Neurocrine Biosciences (NBIX) Net Cash Flow (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Net Cash Flow of -$446.5 million for Q1 2026, down 219.77% on a QoQ basis from $372.8 million in Q4 2025, and down 1047.81% year-over-year from $47.1 million in Q1 2025.
Neurocrine Biosciences (NBIX) Net Cash Flow (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$446.5 million for Q1 2026.
- Quarterly Net Cash Flow fell 1047.81% year-over-year to -$446.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.4 million (up 135.81% YoY) and the FY2025 annual result came in at $480.0 million, up 2751.93% from the prior year.
- Net Cash Flow was -$446.5 million for Q1 2026 at Neurocrine Biosciences, down from $372.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $372.8 million in Q4 2025 and bottomed at -$446.5 million in Q1 2026.
- A 5-year average of -$4.0 million and a median of $48.9 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow soared 421.93% — and 2026, when it tumbled 1047.81%.
- Neurocrine Biosciences' Net Cash Flow stood at $52.0 million in 2022, then tumbled by 182.5% to -$42.9 million in 2023, then plunged by 169.93% to -$115.8 million in 2024, then surged by 421.93% to $372.8 million in 2025, then slumped by 219.77% to -$446.5 million in 2026.
- Business Quant data shows NBIX's Net Cash Flow at -$446.5 million in Q1 2026, $372.8 million in Q4 2025, and $76.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 15.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -446.50 Mn |
| Mar 31, 2026 | -446.50 Mn |
| Dec 31, 2025 | 372.80 Mn |
| Dec 31, 2025 | 372.80 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | 69.70 Mn |
| Jun 30, 2025 | 69.70 Mn |
| Mar 31, 2025 | -38.90 Mn |
| Mar 31, 2025 | -38.90 Mn |
| Dec 31, 2024 | -115.80 Mn |
| Dec 31, 2024 | -115.80 Mn |
| Sep 30, 2024 | 209.10 Mn |
| Sep 30, 2024 | 209.10 Mn |
| Jun 30, 2024 | -256.60 Mn |
| Jun 30, 2024 | -256.60 Mn |
| Mar 31, 2024 | 145.20 Mn |
| Mar 31, 2024 | 145.20 Mn |
| Dec 31, 2023 | -42.90 Mn |
| Dec 31, 2023 | -42.90 Mn |